Home Cart Sign in  
Chemical Structure| 102562-86-7 Chemical Structure| 102562-86-7

Structure of 102562-86-7

Chemical Structure| 102562-86-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 102562-86-7 ]

CAS No. :102562-86-7
Formula : C8H10N2O
M.W : 150.18
SMILES Code : NCC1=CC=CC(=C1)C(N)=O
MDL No. :MFCD07186292
InChI Key :HYHLWVJLJXARGY-UHFFFAOYSA-N
Pubchem ID :10103327

Safety of [ 102562-86-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P301+P312+P330

Computational Chemistry of [ 102562-86-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 11
Num. arom. heavy atoms 6
Fraction Csp3 0.12
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 42.21
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

69.11 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.91
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

-4.76
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.09
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.65
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.58
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

-0.51

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

1.96
Solubility 13600.0 mg/ml ; 90.4 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

3.94
Solubility 1300000.0 mg/ml ; 8650.0 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Highly soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.01
Solubility 1.45 mg/ml ; 0.00968 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-10.6 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.0

Application In Synthesis of [ 102562-86-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 102562-86-7 ]

[ 102562-86-7 ] Synthesis Path-Downstream   1~15

YieldReaction ConditionsOperation in experiment
The reaction was pressurised to 60 psi at room temperature with hydrogen, and stirred for 18 hours. Starting material remained, so a further aliquot of 10% palladium on carbon (500 mg) was added and the procedure was repeated. The reaction mixture was filtered through arbocel washing with acetic acid and the filtrate was concentrated under reduced pressure. The residue was azeotroped with toluene and purified by flash chromatography on silica gel eluding with dichloromethane:methanol:0.88 ammonia (100:0:0 changing to 90:10:1 then 85:15:1.5, by volume) to provide the title compound (5.3 g) as a colourless oil. 1H NMR (400 MHz, CD3OD): delta=3.83 (s, 2H), 7.39 (dd, 1H), 7.49 (d, 1H), 7.73 (d, 1H), 7.81 (s, 1H).
  • 2
  • [ 102562-86-7 ]
  • [ 117918-23-7 ]
  • [ 858780-85-5 ]
  • 3
  • [ 1027039-32-2 ]
  • [ 102562-86-7 ]
  • [ 950598-86-4 ]
  • 4
  • [ 102562-86-7 ]
  • (R)-3-((2S,3S)-3-Amino-2-hydroxy-4-phenyl-butyryl)-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-carbamoyl-benzylamide [ No CAS ]
  • 5
  • [ 102562-86-7 ]
  • [ 858781-00-7 ]
  • 6
  • [ 102562-86-7 ]
  • (R)-3-{(2S,3S)-3-[2-(2,6-Dimethyl-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyryl}-5,5-dimethyl-thiazolidine-4-carboxylic acid 3-carbamoyl-benzylamide [ No CAS ]
  • 7
  • [ 102562-86-7 ]
  • [ 227616-77-5 ]
  • [ 639831-70-2 ]
YieldReaction ConditionsOperation in experiment
10% With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine; In DMF (N,N-dimethyl-formamide); at 20℃; for 14h; To a solution of Intermediate 1h (50 mg, 0.152 mmol) and <strong>[102562-86-7]3-aminomethyl-benzamide</strong> (60 mg, 0.228 mmol) in 2 mL DMF, were added iPr2Net (106 muL, 0.608 mmol), HOAT (41.4 mg, 0.304 mmol) and EDCI (35 mg, 0.182 mmol). The mixture was stirred at rt for 14 h, then was diluted with EtOAc. The organic phase was washed with H2O, 1N HCl, H2O, 0.1 N, NaOH, and brine, dried (Na2SO4), and concentrated. The crude product was recrystallized from methanol to afford 7.2 mg (10%) of Example 24. MS (HR-ESI) calculated for C24H24N5O5 (M+H+), found 462.1787; MS (ESI) 462.3 (M+H+), 484.3 (M+Na+); 1H NMR (300 MHz, CD3OD) delta. 8.51 (br. S, 1H), 7.84 (s, 1H), 7.78 (d, J=7.7, 1H), 7.53-7.31 (m, 7H), 5.20 (s, 2H), 5.13 (dd, J=3.0, 1.0, 1H), 4.61-4.37 (m, 2H), 3.25-3.16 (m, 1H), 3.12-3.03 (m, 1H), 2.66-2.55 (m, 1H), 2.32-2.24 (m, 1H).
  • 8
  • bromoacetal resin [ No CAS ]
  • [ 102562-86-7 ]
  • C12H17N2O3Pol [ No CAS ]
YieldReaction ConditionsOperation in experiment
In dimethyl sulfoxide; at 60℃; for 12h; Step l 5 A bromoacetal resin (37mg, 0.98 mmol/g) and a solution of <strong>[102562-86-7]3-(aminomethyl)benzamide</strong> in DMSO (1.4 mL) were placed in a Robbins block (FlexChem) having 96 well plates. The reaction mixture was shaken at 60C using a rotating oven [Robbins Scientific] for 12 hours. The resin was washed with DMF, MeOH, and then DCM
  • 9
  • [ 675-10-5 ]
  • [ 102562-86-7 ]
  • [ 1196586-53-4 ]
  • 10
  • [ 1123738-14-6 ]
  • [ 102562-86-7 ]
  • [ 1123738-78-2 ]
  • 11
  • [ 1185465-25-1 ]
  • [ 102562-86-7 ]
  • C22H28N4O4 [ No CAS ]
  • 12
  • [ 102562-86-7 ]
  • [ 135447-09-5 ]
  • [ 1325217-42-2 ]
  • 13
  • [ 102562-86-7 ]
  • [ 187998-35-2 ]
  • C19H17ClN4O2 [ No CAS ]
  • 14
  • [ 257640-86-1 ]
  • [ 102562-86-7 ]
  • N-(3-carbamoylbenzyl)-9-fluoro-7-hydroxy-3-methyl-5-oxo-2,3-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-6-carboxamide [ No CAS ]
  • 15
  • [ 102562-86-7 ]
  • 6,8-dibromo-3-(prop-1-en-2-yl)imidazo[1,2-a]pyrazine [ No CAS ]
  • C17H16BrN5O [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 102562-86-7 ]

Aryls

Chemical Structure| 126534-87-0

A239285 [126534-87-0]

3-Formylbenzamide

Similarity: 1.00

Chemical Structure| 55-21-0

A446394 [55-21-0]

Benzamide

Similarity: 1.00

Chemical Structure| 20188-40-3

A200114 [20188-40-3]

4-(Aminomethyl)benzamide hydrochloride

Similarity: 0.97

Chemical Structure| 88-96-0

A152148 [88-96-0]

Phthalamide

Similarity: 0.92

Chemical Structure| 2760-98-7

A352388 [2760-98-7]

Isophthalic dihydrazide

Similarity: 0.87

Amides

Chemical Structure| 126534-87-0

A239285 [126534-87-0]

3-Formylbenzamide

Similarity: 1.00

Chemical Structure| 55-21-0

A446394 [55-21-0]

Benzamide

Similarity: 1.00

Chemical Structure| 20188-40-3

A200114 [20188-40-3]

4-(Aminomethyl)benzamide hydrochloride

Similarity: 0.97

Chemical Structure| 88-96-0

A152148 [88-96-0]

Phthalamide

Similarity: 0.92

Chemical Structure| 2760-98-7

A352388 [2760-98-7]

Isophthalic dihydrazide

Similarity: 0.87

Amines

Chemical Structure| 126534-87-0

A239285 [126534-87-0]

3-Formylbenzamide

Similarity: 1.00

Chemical Structure| 55-21-0

A446394 [55-21-0]

Benzamide

Similarity: 1.00

Chemical Structure| 20188-40-3

A200114 [20188-40-3]

4-(Aminomethyl)benzamide hydrochloride

Similarity: 0.97

Chemical Structure| 88-96-0

A152148 [88-96-0]

Phthalamide

Similarity: 0.92

Chemical Structure| 2760-98-7

A352388 [2760-98-7]

Isophthalic dihydrazide

Similarity: 0.87